PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+42.22%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$3.47B
AUM Growth
+$3.47B
(+0.85%)
Cap. Flow
-$145M
Cap. Flow
% of AUM
-4.17%
Top 10 Holdings %
Top 10 Hldgs %
46.93%
Holding
128
New
11
Increased
19
Reduced
26
Closed
30
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$116M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$109M |
| 3 |
Vaxcyte
PCVX
|
$56.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
$51.3M |
| 5 |
Acrivon Therapeutics
ACRV
|
$34.7M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$158M |
| 2 |
Relmada Therapeutics
RLMD
|
$88.2M |
| 3 |
Solid Biosciences
SLDB
|
$53.4M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$43.3M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$28.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amicus Therapeutics
FOLD
$2.34B
| $338M | 9.48% | 27,642,917 +270,000 | +1% | +$3.3M |
|
2
Amylyx Pharmaceuticals
AMLX
$836M
| $225M | 6.32% | 6,088,333 +616,300 | +11% | +$22.8M |
|
|
3
Madrigal Pharmaceuticals
MDGL
$9.76B
| $212M | 5.97% | 731,932 +400,909 | +121% | +$116M |
|
|
CERE
4
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $205M | 5.77% | 6,511,727 | – | – |
|
|
RXDX
5
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $133M | 3.75% | 1,212,694 -255,818 | -17% | -$28.1M |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $128M | 3.58% | 4,880,719 -166,545 | -3% | -$4.35M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $109M | 3.07% | +960,000 | New | +$109M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $99.3M | 2.79% | 2,191,425 -593,371 | -21% | -$26.9M |
|
|
LIAN
9
DELISTED
LianBio American Depositary Shares
LIAN
| $94.4M | 2.65% | 57,558,451 | – | – |
|
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $84.1M | 2.36% | 649,250 +396,250 | +157% | +$51.3M |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $81.7M | 2.29% | 3,313,783 +425,923 | +15% | +$10.5M |
|
12
Arcellx
ACLX
$3.85B
| $80.5M | 2.26% | 2,598,305 +132,900 | +5% | +$4.12M |
|
13
Aldeyra Therapeutics
ALDX
$351M
| $79M | 2.22% | 11,350,085 | – | – |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $75.8M | 2.13% | 1,921,273 -201,262 | -9% | -$7.94M |
|
15
Crinetics Pharmaceuticals
CRNX
$2.92B
| $73.9M | 2.08% | 4,039,276 -1,281,756 | -24% | -$23.5M |
|
|
BLU
16
DELISTED
BELLUS Health Inc.
BLU
| $73.1M | 2.05% | 8,891,027 -1,356,046 | -13% | -$11.1M |
|
|
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
| $68.1M | 1.91% | 2,617,691 -852,872 | -25% | -$22.2M |
|
18
Nuvalent
NUVL
$5.52B
| $67.2M | 1.89% | 2,255,007 +600,000 | +36% | +$17.9M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $63.7M | 1.79% | 9,971,780 -276,844 | -3% | -$1.77M |
|
|
20
Vaxcyte
PCVX
$4B
| $56.1M | 1.58% | +1,170,000 | New | +$56.1M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $52.4M | 1.47% | 506,481 +170,000 | +51% | +$17.6M |
|
22
ADMA Biologics
ADMA
$4.12B
| $46.2M | 1.3% | 11,900,255 +966,868 | +9% | +$3.75M |
|
23
MeiraGTx Holdings
MGTX
$587M
| $45.4M | 1.27% | 6,963,277 | – | – |
|
24
Treace Medical Concepts
TMCI
$464M
| $44.7M | 1.26% | 1,946,403 +344,424 | +21% | +$7.92M |
|
25
Veru
VERU
$47.6M
| $41.5M | 1.17% | 7,858,011 +3,965,011 | +102% | +$20.9M |
|